WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory
AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig 08 June 2017
AstraZeneca enters agreement with Recordati for Seloken in Europe 22 May 2017
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer 12 May 2017
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK 02 May 2017
First collaborative definition of patient centricity 05 April 2017
Tagrisso (osimertinib) receives US FDA full approval 31 March 2017
Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 28 March 2017
AstraZeneca and Circassia enter strategic collaboration in respiratory disease 17 March 2017
MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897 07 March 2017
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes 28 February 2017
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
  • AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
  • FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
  • Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
  • Bayer selects Pharmaron as partner organization

Research & Development

  • The gut may be involved in the development of multiple sclerosis
  • Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer
  • Investigational drugs reduce risk of death from Ebola virus disease
  • Pharmacist-led interventions may help prevent cardiovascular disease
  • A protein tag to study the immune system
  • Industry executives: Profits drive rising prices for MS drugs
  • Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery

Conferences & Events

  • Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
  • SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
  • SMi's 4th Annual 3D Cell Culture
  • Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
  • RNA Therapeutics Conference and Focus Day
  • CPhI Worldwide announces the winners of the 16th Pharma Awards
  • CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023

Regulatory Affairs

  • FDA approves first generics of Gilenya
  • FDA approves novel treatment to target abnormality in sickle cell disease
  • FDA approves first treatment for inherited rare disease
  • FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
  • FDA approves first therapy to treat patients with rare blood disorder
  1. You are here:  
  2. Home
  3. AstraZeneca

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE